Shares of Simulations Plus (SLP) have gained 1.1% over the past four weeks to close the last trading session at $30.70, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $54.50 indicates a potential upside of 77.5%.The average comprises four short-term price targets ranging from a low of $47 to a high of $65, with a standard deviation of $7.94. While the lowest estimate indicates ...

Simulations Plus, Inc. (SLP) reported fourth-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 6 cents per share, which declined 66.7% year over year. The figure, however, beat the Zacks Consensus Estimate of 4 cents per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Quarterly revenues jumped 19% year over year to $18.7 million due to higher software and services revenues in the Clinical Pharmacology & Pharmacometrics (CPP), higher software ...

Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this maker of software used in pharmaceutical research would post earnings of $0.16 per share when it actually produced earnings of $0.19, delivering a surprise of 18.75%.Ov ...

Exhibit 99.1 S+ SimulationsPlus Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 LANCASTER, CA, October 23, 2024 – Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelli ...

Simulations Plus, Inc. (SLP) has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024. Over the past year, Simulations Plus made two major acquisitions, including the largest in its corporate history. In June 2024, the company acquired Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders for about $100 million, expanding its footprint across the drug development continuu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended May 31, 2024 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-32046 Simulations Plus, Inc. (Name of registrant as specified in its charter) (State or other jurisdiction of ...

Financial Data and Key Metrics Changes - Total revenue increased by 14% to $18.5 million in Q3 2024, with Software revenue up 12% and Services revenue up 18% [30][4] - Diluted earnings per share were $0.15 compared to $0.20 last year, while adjusted diluted earnings per share were $0.19 compared to $0.21 last year [33][14] - Total gross margin was 71%, down from 82% last year, with Software gross margin at 88% versus 91% and Services gross margin at 41% versus 63% [11][12] Business Line Data and Key Metrics Changes - Software segment revenues increased by 12% in Q3 and 14% for the nine-month period, driven by renewals and upsells [5] - Physiologically Based Pharmacokinetics (PBPK) business unit saw a 7% revenue increase in Q3 and 9% year-to-date, adding 14 new customers [6] - Quantitative Systems Pharmacology (QSP) business unit revenues surged by 80% in Q3 and 78% year-to-date, although quarterly results can be variable due to high license costs [7] - Services revenues in the Clinical Pharmacology & Pharmacometrics (CPP) business unit grew by 27% in Q3 and 16% year-to-date, while QSP services revenue grew by 49% in Q3 and 74% year-to-date [8] Market Data and Key Metrics Changes - The market funding environment for biotech is improving, with signs of recovery particularly for companies with drug candidates in clinical trials [25] - Customer renewal rates for the trailing 12 months were 92% based on fees and 84% based on accounts [12] Company Strategy and Development Direction - The company aims to achieve full-year revenue guidance of $69 million to $72 million, with year-over-year growth expected between 15% to 20% [17] - The acquisition of Pro-ficiency is expected to enhance the company's offerings and expand its total addressable market to $8 billion [36][29] - The company is focused on investing in growth initiatives rather than continuing its quarterly cash dividend [15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding large pharmaceutical client spending, noting a mix of increased and conservative expenditures [25] - The company anticipates that the integration of Pro-ficiency will progress according to plan and is expected to contribute positively to fiscal year 2025 earnings [61][29] Other Important Information - Total operating expenses were 61% of revenue compared to 57% last year, primarily due to acquisition costs and increased compensation expenses [13] - The company ended the quarter with $119 million in cash and investments, remaining well-capitalized with no debt [34] Q&A Session Summary Question: What is the outlook for organic revenue growth in 2025? - Management indicated that the biosimulation market is growing at 12% to 15%, and they expect potential improvements in fiscal year 2025 [64] Question: Can you provide updates on Pro-ficiency's contribution? - The expected contribution from Pro-ficiency in fiscal year 2025 remains at $15 million to $18 million, with potential for better performance [65] Question: What factors impacted the adjusted EBITDA margin this quarter? - The adjusted EBITDA margin was impacted by costs associated with a significant software release and increased hiring expenses [66]

Financial Performance - Revenue for 3Q24 reached $18.5 million, a 14% increase compared to $16.2 million in 3Q23[31] - Year-to-date (YTD) revenue for FY24 was $51.3 million, representing a 17% growth from $43.9 million in the same period of FY23[33] - Gross profit for 3Q24 was $13.3 million, resulting in a gross margin of 71%, which is lower than the 82% gross margin in 3Q23[31] - Net income for 3Q24 was $3.1 million ($0.15 diluted EPS), compared to $4.0 million ($0.20 diluted EPS) in 3Q23[31] - Adjusted EBITDA for 3Q24 was $5.7 million, representing 31% of revenue, compared to $6.5 million, or 40% of revenue, in 3Q23[31] Revenue Breakdown - Software revenue in 3Q24 was $11.9 million, an 12% increase from $10.6 million in 3Q23[42] - Services revenue in 3Q24 was $6.6 million, an 18% increase from $5.6 million in 3Q23[42] - The revenue mix in 3Q24 was 64% software and 36% services[42] - Total backlog was $19.6 million [51] Software Performance - Cheminformatics (ADMET Predictor) software revenue grew by 15% in 3Q24 [55] - Physiologically Based Pharmacokinetics (GastroPlus) software revenue grew by 7% in 3Q24 [56] - Clinical Pharmacology & Pharmacometrics (MonolixSuite) software revenue grew by 13% in 3Q24 [56]

Financial Performance - Total revenue for the third quarter of fiscal 2024 increased 14% to $18.5 million compared to the same quarter in 2023[15] - Software revenue rose 12% to $11.9 million, accounting for 64% of total revenue, while services revenue increased 18% to $6.6 million, representing 36% of total revenue[15] - Gross profit remained constant at $13.3 million, with a gross margin of 71%[15] - Adjusted EBITDA for the quarter was $5.7 million, representing 31% of total revenue[15] - Net income for the quarter was $3.1 million, with diluted EPS of $0.15, down from $4.0 million and $0.20 in the same quarter last year[15] - Total revenue for the first nine months of fiscal 2024 increased 17% to $51.3 million, with software revenue at $31.1 million and services revenue at $20.2 million[5] - Adjusted EBITDA for FY 2024 YTD is reported at $9.1 million, compared to $10.0 million for the full year of 2023[32] - The company reported a net income of $4.0 million for Q3 FY 2024, compared to $4.2 million for FY 2023[32] - Net income for Q3 2023 was $4.0 million, a decrease from $4.2 million in Q2 2023, while FY 2023 net income stands at $10.0 million[45] - Adjusted EBITDA for Q3 2023 reached $6.5 million, compared to $6.2 million in Q2 2023, with FY 2023 total at $20.6 million[48] - Total revenue for Q3 2023 was $16.2 million, up from $15.8 million in Q2 2023, with FY 2023 revenue at $59.6 million[50] Guidance and Strategy - The company maintains full-year revenue guidance of $69 million to $72 million, with expected revenue growth of 15% to 20%[21] - The company has decided to discontinue its quarterly cash dividend to focus on growth initiatives, with the final dividend of $0.06 per share to be paid on August 5, 2024[22] - The company remains committed to a disciplined growth strategy aimed at delivering long-term returns for shareholders[34] Assets and Liabilities - Total assets increased to $192.7 million as of May 31, 2024, compared to $186.1 million on August 31, 2023, reflecting a growth of approximately 3.4%[29] - Cash and cash equivalents rose significantly to $109.1 million from $57.5 million, marking an increase of 89.8%[29] - Total current liabilities decreased to $11.3 million from $12.0 million, a reduction of approximately 5.6%[29] - Retained earnings increased to $30.7 million from $25.2 million, reflecting a growth of 21.9%[29] - Total shareholders' equity rose to $180.9 million from $170.0 million, an increase of approximately 6.0%[29] Business Developments - The acquisition of Pro-ficiency is progressing as planned, enhancing the company's capabilities in simulations and AI technologies[20] - The launch of GastroPlus X, a new generation of PBPK/PBBM modeling software, is expected to significantly contribute to the company's offerings[19] - The newly formed Clinical Simulations and Medical Communications (CSMC) business unit is expected to contribute approximately $3 million to fiscal 2024 revenue[34] Customer Metrics - Average Revenue per Customer in the commercial segment was $97.0 thousand, showing a decrease from $110.0 thousand in the previous quarter[30] Operational Metrics - Operating margin for Q3 2023 was 25.2%, compared to 25.6% in Q2 2023, with FY 2023 operating margin at 14.6%[48] - Cash flow from operations in Q3 2023 was $8.5 million, up from $5.5 million in Q2 2023, with FY 2023 cash flow totaling $21.9 million[48] - The backlog for services stood at $18.0 million in Q3 2023, a decrease from $19.5 million in Q2 2023[49] Expenses - Mergers & acquisitions expenses for Q3 2023 were $0.4 million, up from $0.1 million in Q2 2023, with total expenses for FY 2023 at $1.7 million[45]

Core Insights - The upcoming earnings report for Simulations Plus is expected to show a decline in earnings per share (EPS) by 15% year-over-year, with a consensus estimate of $0.17 per share [12]. - Revenue for the quarter is projected to be $18.07 million, reflecting an increase of 11.3% compared to the same quarter last year [2]. - The consensus EPS estimate has been revised down by 52.63% over the last 30 days, indicating a significant reassessment by analysts [13]. Earnings Prediction Insights - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Simulations Plus is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [5]. - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Simulations Plus currently holds a Zacks Rank of 4 (Sell), which complicates the prediction of an earnings beat [22]. Historical Performance - Over the last four quarters, Simulations Plus has only beaten consensus EPS estimates once [23]. - The company's earnings surprise history is a critical factor for analysts when estimating future earnings, as it reflects the company's ability to meet or exceed expectations [26]. Market Reactions - The stock's movement post-earnings report will depend on how actual results compare to expectations, with potential for upward movement if results exceed estimates, and downward movement if they fall short [11]. - It is noted that an earnings beat does not guarantee a stock price increase, as other factors may influence investor sentiment [17]. Conclusion - Investors should closely monitor the upcoming earnings report on July 2, 2024, as it may significantly impact the stock's performance based on the comparison of actual results to consensus estimates [11].